NORAD and esophageal squamous cell carcinoma: NORAD knockdown reduces the efficiency of HR by inhibiting ATR/Chk1 signaling and inhibits DNA repair components, including ATM, ATR, Chk1, and Chk2, thereby enhancing the therapeutic effect of IR on ESCC [172].